Ilknur Yilmaz

Dr. Ilknur Yilmaz

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2019 in Journal of Visualized Experiments
Verified
Journal Article
Closed access
PDF file
AAAhmed Aly
Ahmed Aly
GDGozde Deveci
Gozde Deveci
IYIlknur Yilmaz
Ilknur Yilmaz
AAAmanah Abraham
Amanah Abraham
AGAneesa Golshan
Aneesa Golshan
RHRobert J. Hart
Robert J. Hart
Recent advances in genetics and systems biology technologies have promoted our understanding of the biology of malaria parasites on the molecular level. However, effective malaria parasite targets for vaccine and chemotherapy development are still limited. This is largely due to the unavailability of relevant and practical in vivo infection models for human Plasmodium species, most notably for P. falciparum and P. vivax. Therefore, rodent malaria species have been extensively used as practical alternative in vivo models for malaria vaccine, drug targeting, immune response, and functional characterization studies of conserved Plasmodiumspp. genes. Indeed, rodent malaria models have proven to be invaluable, especially for exploring mosquito transmission and liver stage biology, and were indispensable for immunological studies. However, there are discrepancies in the methods used to evaluate the phenotypes of transgenic and wild-type asexual and sexual blood-stage parasites. Examples of these discrepancies are the choice of an intravenous vs. intraperitoneal infection of rodents with blood-stage parasites and the evaluation of male gamete exflagellation. Herein, we detail standardized experimental methods to evaluate the phenotypes of asexual and sexual blood stages in transgenic parasites expressing reporter-gene or wild-type rodent malaria parasite species. We also detail the methods to evaluate the phenotypes of malaria parasite mosquito stages (gametes, ookinetes, oocysts, and sporozoites) inside Anopheles mosquito vectors. These methods are detailed and simplified here for the lethal and non-lethal strains of P. berghei and P. yoelii but can also be applied with some adjustments to P. chabaudi and P. vinckei rodent malaria species.

9 September 2022 in Microbiological Research
Verified
Journal Article
Closed access
MKMohd Kamil
Mohd Kamil
UKUmit Y. Kina
Umit Y. Kina
GDGozde Deveci
Gozde Deveci
SASevim N. Akyuz
Sevim N. Akyuz
IYIlknur Yilmaz
Ilknur Yilmaz
AAAhmed Aly
Ahmed Aly

8 April 2025 in European Polymer Journal
Verified
Journal Article
Closed access
EMEda Nur Yetiskin Morkan
Eda Nur Yetiskin Morkan
IYIlknur Yilmaz
Ilknur Yilmaz
BABusra Akgul
Busra Akgul
EAEmrah Sefik Abamor
Emrah Sefik Abamor
TOTulin Ozbek
Tulin Ozbek
MTMurat Topuzogullari
Murat Topuzogullari

10 January 2020 in Vaccines
Verified
Journal Article
Open access
PDF file
SRSophia M. Reeder
Sophia M. Reeder
EREmma L. Reuschel
Emma L. Reuschel
MBMamadou A. Bah
Mamadou A. Bah
KYKun Yun
Kun Yun
NTNicholas Tursi
Nicholas Tursi
AAAhmed Aly
Ahmed Aly
The need for a malaria vaccine is indisputable. A single vaccine for Plasmodium pre-erythrocytic stages targeting the major sporozoite antigen circumsporozoite protein (CSP) has had partial success. Additionally, CD8+ T cells targeting liver-stage (LS) antigens induced by live attenuated sporozoite vaccines were associated with protection in human challenge experiments. To further evaluate protection mediated by LS antigens, we focused on exported pre-erythrocytic proteins (exported protein 1 (EXP1), profilin (PFN), exported protein 2 (EXP2), inhibitor of cysteine proteases (ICP), transmembrane protein 21 (TMP21), and upregulated in infective sporozoites-3 (UIS3)) expressed in all Plasmodium species and designed optimized, synthetic DNA (synDNA) immunogens. SynDNA antigen cocktails were tested with and without the molecular adjuvant plasmid IL-33. Immunized animals developed robust T cell responses including induction of antigen-specific liver-localized CD8+ T cells, which were enhanced by the co-delivery of plasmid IL-33. In total, 100% of mice in adjuvanted groups and 71%–88% in non-adjuvanted groups were protected from blood-stage disease following Plasmodium yoelii sporozoite challenge. This study supports the potential of synDNA LS antigens as vaccine components for malaria parasite infection.

16 September 2024 in Journal of Forensic and Legal Medicine
Verified
Journal Article
Closed access
SKSukriye Karadayı
Sukriye Karadayı
IYIlknur Yilmaz
Ilknur Yilmaz
TOTulın Ozbek
Tulın Ozbek
BKBeytullah Karadayı
Beytullah Karadayı

16 February 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
PRPaul J.F. Rider
Paul J.F. Rider
MKMohd Kamil
Mohd Kamil
IYIlknur Yilmaz
Ilknur Yilmaz
HAHabibe N. Atmaca
Habibe N. Atmaca
MKMerve Kalkan-Yazici
Merve Kalkan-Yazici
AAAhmed S. I. Aly
Ahmed S. I. Aly
Here, we present the construction of an attenuated herpes simplex virus type-1 (HSV-1)-vectored vaccine, expressing three liver-stage (LS) malaria parasite exported proteins (EXP1, UIS3 and TMP21) as fusion proteins with the VP26 viral capsid protein. Intramuscular and subcutaneous immunizations of mice with a pooled vaccine, composed of the three attenuated virus strains expressing each LS antigen, induced sterile protection against the intravenous challenge of Plasmodium yoelii 17X-NL salivary gland sporozoites. Our data suggest that this malaria vaccine may be effective in preventing malaria parasite infection using practical routes of immunization in humans.